|
Dr. Baker is currently at Gilead Sciences, following Gilead's acquisition of Corus in 2006. He joined Corus Pharma as Vice President, Research in June 2002, with more than 20 years of research and drug discovery experience. Prior to joining Corus Pharma, Dr. Baker was Chief Operating Officer and VP Research for Optimer Pharmaceuticals, Inc., where he focused on developing novel therapeutics for infectious disease and cancer. Previously, Dr. Baker served as Senior Vice President of Research and Preclinical Development for PathoGenesis Corporation. Prior to PathoGenesis, Dr. Baker was Associate Research Fellow at Abbott Laboratories, where he directed research in cardiovascular and anti-infective drug discovery. While at Abbott his research developed the 11, 12 carbamate reaction sequence and full sugar analogs technology that enabled the ketolide class of macrolide antibiotics. Dr. Baker received his Ph.D. in organic chemistry from the University of Illinois, Champaign and his BS degree in chemistry from the University of Washington. | 